Opsona has contracted with Bill to function as an external Program Lead for one of our high priority drug discovery targets. Bill is very effective at driving the research, coordinating all of activities across the virtual infrastructure and communicating back to myself and the company Board of Directors. We are very pleased with the progress and results and would highly recommend his services.
Mark Heffernan, Ph.D.
CEO, Opsona Therapeutics
I would like to take this opportunity to recommend William Harte, PhD as a drug discovery research consultant. I am the scientific director of a small non-profit that has been funding academic research to find a treatment for a rare inherited disease called Usher IIIa. This disease causes progressive blindness and deafness. I hired Dr. Harte to both help us streamline our translational research efforts as well as provide us with "reality checks" concerning the feasibility, costs and timelines necessary to develop the therapeutic compounds that our scientists have discovered in a small molecule screening project. Dr. Harte was recommended to me by a colleague who worked with him while he was an executive at Amgen. Dr. Harte quickly brought himself up to speed on our research progress and goals. He was able to adapt to the advantages and disadvantages our small and nimble structure. He is proving invaluable in our drug discovery efforts. His expertise has already saved our organization many times his consulting fee. His efficient, affable style makes working with Bill a pleasure. He is an excellent listener who rather than presenting a dogmatic approach, he tailored his advice to our needs and resources. He has gained the respect of our researchers (most of whom are full Professors and/or Department Chairmen), our contract research collaborators and the family that funds our research. William Harte has been and continues to be a valuable asset to our organization. We feel his work is optimizing our chances for success. If you have any questions, please do not hesitate to contact me.
Top qualities: Great Results, Expert, High Integrity
David A. Saperstein, MD
Scientific Director Usher III Initiative/Hope for Vision
Receptos is a new company based on GPCR structure based drug discovery technology from my lab at The Scripps Research Institute. Given his broad expertise, Bill was engaged by one of our early venture backers to perform due-diligence review. Receptos has subsequently hired Bill as a consultant to advise us on the technology platform that we seek to leverage through external alliances as well as our future drug discovery programs. In this regard, Bill has suggested mid-term client deliverables that would not only have significant value to our partners, but also accelerate our internal discovery efforts. In summary, Bill's command of many different aspects of the drug discovery process serves him well as an advisor.
Co-founder of Receptos
After forming a start up company based on intellectual property emanating from my labs here at
Brent R. Stockwell, Ph.D.
Early Career Scientist, Howard Hughes Medical Institute
Associate Professor with Tenure
Department of Biological Sciences and Department of Chemistry,
Founder, Solaris Therapeutics